Hydromorphone for ICU pain relief study
Part of Brain & nervous system clinical trials.
This study tests a pain medicine called hydromorphone for people in the ICU who need a breathing tube. The goal is to see how well it works and if it's safe for managing pain and sedation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are in the ICU and likely need a breathing machine for at least 24 hours.
- You or your family must agree to join the study.
- You are not allergic to any opioid pain medicines or related drugs.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pain medicine called oxycodone for patients on breathing machines in the ICU. It aims to see if it provides safe and effective long-term pain control.
This trial tests a new pain and sedation medicine called Oliceridine for patients in the ICU who are on a breathing machine. It aims to see if it works safely and effectively to help you stay comfortable.
This trial tests a new sedation protocol for adults in intensive care who need strong pain relief or sedation medicines. It aims to make sedation safer and more comfortable, and includes people on ECMO (a heart-lung machine) or a ventilator (breathing machine) for severe breathing problems.
This trial tests a quick-acting pain medicine (hydromorphone) given through a vein to treat severe chest pain. It may be an option for people experiencing acute pain who haven't been helped by other medicines.
This study tests a painkiller called nalbuphine for ICU patients on a breathing machine. It aims to see if it controls pain as well as or better than usual care, with fewer side effects.
This study compares different pain medicines for patients in the ICU who are not on a breathing machine. It aims to find which approach works best for moderate to severe pain while keeping patients safe.
Hear when a new Analgesia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.